The FDA is finally fast-tracking commercialization of new Coronavirus test kits. Rapid diagnostics is the key to preventing a pandemic. How to invest.
We have argued since July 2001 that plagues and bioterrorism are a real and increasingly dangerous threat to world health. In WATMTU March 1, 2020, we highlighted that the U.S. is now moving to aggressively expand testing after weeks of delays with problematic test kits and overly-tight restrictions on who should be tested.
Thermo Fisher Scientific’s $11.5 billion deal this week for Qiagen NV, a leading developer of diagnostics tests, including Coronavirus, validates the sector as a huge growth business. Qiagen has gained 227.4% since our initial 2006 recommendation, versus 141.1% for the S&P 500 (see WILTW February 9, 2006).
Coronavirus (i.e. COVID-19) is only the first of many new virulent pathogens the world will likely face in the y...
Want to read more?SUBSCRIBE TODAY
Already a subscriber? Login here.